Vivek Subbiah Robert E Brown Mary F McGuire Jamie Buryanek Filip Janku Anas Younes David Hong
10.18632/oncotarget.1468
Oncotarget
2014 Jan 15;5(1):95-102.
CC BY
https://pubmed.ncbi.nlm.nih.gov/24395633/
Antineoplastic Combined Chemotherapy Protocols / therapeutic use Hodgkin Disease / drug therapy
Antineoplastic Combined Chemotherapy Protocols / therapeutic use Hodgkin Disease / drug therapy Case Reports Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Adult Female Hodgkin Disease / immunology Hodgkin Disease / pathology Humans Hydroxamic Acids / administration & dosage Immunologic Factors / administration & dosage Molecular Targeted Therapy Phosphoinositide-3 Kinase Inhibitors Sirolimus / administration & dosage Sirolimus / analogs & derivatives TOR Serine-Threonine Kinases / antagonists & inhibitors Vorinostat Hydroxamic Acids Immunologic Factors Phosphoinositide-3 Kinase Inhibitors Vorinostat temsirolimus MTOR protein, human TOR Serine-Threonine Kinases Sirolimus
PMC3960191
24395633
A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma
2014